Inovio Stock Falls 21% After Hours: Here's What's Going On

Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

Jefferies analyst Roger Song upgrades Inovio Pharmaceuticals (NASDAQ:INO) from Hold to Buy and raises the price target from $1.8 to $3.

Inovio Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS results.

8-K filing — INOVIO PHARMACEUTICALS, INC. (INO)

Filed: 2026-08-12 AccNo: 0001055726-26-000024 Size: 271 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Inovio Pharmaceuticals Q2 EPS $(0.07) Beats $(0.22) Estimate

Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.22) by 68.18 percent. This is a 88.52 percent increase over losses of $(0.61) per share

Continuim Equity Partners Closes Oversubscribed Fund III at $548 Million – Bringing AUM to Over $1 Billion

Continuim Equity Partners, a Pittsburgh-based private equity firm, closed Fund III with $548 million in commitments after just 32 days in market, significantly oversubscribed. The close brings the firm's total assets under management to over $1 billion. Since its 2021 founding, Continuim has completed 11 platform and 9 add-on acquisitions in the manufacturing and industrial sectors.

Why HubSpot Stock Is Plummeting Today

HubSpot reported Q2 2026 results that beat analyst expectations with $912M revenue and $3.26 EPS, but the stock plunged 20.98% as multiple analysts downgraded the company. Concerns centered on slowing customer additions (7,000 net new customers last quarter) and reduced growth expectations following April pricing strategy changes. However, the company's strong free cash flow growth of 44% year-over-year suggests potential value for contrarian investors.